While value-based medicine is beginning to really take shape in the U.S., the approach has not been at the top of pharma professionals’ agendas. However, that line of thinking is rapidly changing.
According to a 2017 Global Healthcare Leaders survey conducted by Lazard, out of 200 pharmaceutical leaders and 100-plus investors in the health care industry, pricing and reimbursement ranked No. 1 for 88 percent of American executives and 58 percent of European executives.
The kicker? Most subjects said the biggest change facing the market is actually value-based health care and pricing models based on risk.
(Source: PharmaTech.Com, May 24, 2017)